COLESEVELAM HYDROCHLORIDE- colesevelam hydrochloride powder, for suspension
Bryant Ranch Prepack
1 INDICATIONS & USAGE
1.1 Primary Hyperlipidemia
Colesevelam hydrochloride for oral suspension is indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia
Colesevelam hydrochloride for oral suspension is indicated to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) who are unable to reach LDL-C target levels despite an adequate trial of dietary therapy and lifestyle modification.
1.3 Limitations of Use
- Colesevelam hydrochloride should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis.
- The effect of colesevelam hydrochloride on cardiovascular morbidity and mortality has not been determined.
- Colesevelam hydrochloride has not been studied in type 2 diabetes in combination with a dipeptidyl peptidase 4 inhibitor.
- Colesevelam hydrochloride has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.
- Colesevelam hydrochloride has not been studied in children younger than 10 years of age or in premenarchal girls.
2 DOSAGE & ADMINISTRATION
2.1 Testing Prior to Initiation of Colesevelam Hydrochloride
Obtain lipid parameters, including triglyceride (TG) levels before starting colesevelam hydrochloride. Colesevelam hydrochloride is contraindicated in patients with TG levels greater than 500 mg/dL [see Contraindications (4) and Warnings and Precautions (5.1)].
2.2 Recommended Dosage in Primary Hyperlipidemia
The recommended dosage of colesevelam hydrochloride for oral suspension for adults and children 10 to 17 years old with primary hyperlipidemia is 3.75 grams daily.
Colesevelam hydrochloride for oral suspension should be taken as follows:
For Oral Suspension
Take one packet once daily.
2.3 Important Dosing Information for Primary Hyperlipidemia
Colesevelam hydrochloride for oral suspension can be dosed at the same time as a statin or colesevelam hydrochloride for oral suspension and the statin can be dosed apart. Monitor lipid levels within 4 to 6 weeks after initiation of colesevelam hydrochloride for oral suspension.
2.4 Administration Instructions
For Oral Suspension:
To prepare, empty the entire contents of one packet into a glass or cup. Add 1 cup (8 ounces) of water, fruit juice, or diet soft drinks. Stir well and drink. Take colesevelam hydrochloride for oral suspension with meals. Do not take colesevelam hydrochloride for oral suspension in its dry form. Due to tablet size, colesevelam hydrochloride for oral suspension is recommended for use in the pediatric population.
3 DOSAGE FORMS & STRENGTHS
Colesevelam Hydrochloride for Oral Suspension: a white to yellow granular powder containing yellow granules packaged in single dose packets: 3.75 gram single dose packet.
Colesevelam hydrochloride is contraindicated in patients with:
- Serum TG concentrations greater than 500 mg/dL [see Warnings and Precautions (5.1)]
- History of hypertriglyceridemia-induced pancreatitis [see Warnings and Precautions (5.1)]
- A history of bowel obstruction [see Warnings and Precautions (5.2)]
5 WARNINGS AND PRECAUTIONS
5.1 Hypertriglyceridemia and Pancreatitis
Colesevelam hydrochloride, like other bile acid sequestrants, can increase serum TG concentrations. Hypertriglyceridemia can cause acute pancreatitis.
Colesevelam hydrochloride had effects on serum TG (median increase 5% compared to placebo) in trials of patients with primary hyperlipidemia.
Obtain lipid parameters, including TG levels before starting colesevelam hydrochloride and periodically thereafter. Colesevelam hydrochloride is contraindicated in patients with TG levels greater than 500 mg/dL or patients with a history of hypertriglyceridemia-induced pancreatitis [see Contraindications (4)]. Patients with TG levels greater than 300 mg/dL could have greater increases in serum TG levels with colesevelam hydrochloride and may require additional TG monitoring. Instruct patients to discontinue colesevelam hydrochloride and seek prompt medical attention if the symptoms of acute pancreatitis occur (e.g., severe abdominal pain with or without nausea and vomiting). Discontinue colesevelam hydrochloride if TG levels exceed 500 mg/dL [see Adverse Reactions (6.1)].
5.2 Gastrointestinal Obstruction
Postmarketing cases of bowel obstruction have occurred with colesevelam hydrochloride [see Adverse Reactions (6.2)]. Because of its constipating effects, colesevelam hydrochloride is not recommended in patients with gastroparesis, other gastrointestinal motility disorders, and in those who have had major gastrointestinal tract surgery and who may be at risk for bowel obstruction. Colesevelam hydrochloride is contraindicated in patients with a history of bowel obstruction [see Contraindications (4)]. Instruct patients to promptly discontinue colesevelam hydrochloride and seek medical attention if severe abdominal pain or severe constipation occurs.
Because of the tablet size, colesevelam hydrochloride tablets can cause dysphagia or esophageal obstruction. For patients with difficulty swallowing tablets use colesevelam hydrochloride for oral suspension.
5.3 Vitamin K or Fat-Soluble Vitamin Deficiencies
Colesevelam hydrochloride may decrease the absorption of fat-soluble vitamins A, D, E, and K. Patients with a susceptibility to deficiencies of vitamin K (e.g., patients on warfarin, patients with malabsorption syndromes) or other fat-soluble vitamins may be at increased risk when taking colesevelam hydrochloride.
Patients on oral vitamin supplementation should take their vitamins at least 4 hours prior to colesevelam hydrochloride.[see Drug Interactions (7.1)].
5.4 Drug Interactions
Colesevelam hydrochloride reduces gastrointestinal absorption of some drugs. Administer drugs with a known interaction at least 4 hours prior to colesevelam hydrochloride[see Drug Interactions (7)].
Due to the potential for decreased absorption of other drugs that have not been tested for interaction, especially those with a narrow therapeutic index, consider administering at least 4 hours prior to colesevelam hydrochloride[see Clinical Pharmacology (12.3)].
5.5 Risks in Patients with Phenylketonuria (PKU)
Phenylalanine can be harmful to patients with PKU.Colesevelam hydrochloride for oral suspension contains phenylalanine, a component of aspartame. Each 3.75 gram packet contains 33.6 mg of phenylalanine. Before prescribing Colesevelam hydrochloride for oral suspension to a patient with PKU, consider the combined daily amount of phenylalanine from all sources, including colesevelam hydrochloride for oral suspension.
5.6 Macrovascular Outcomes
There have been no clinical studies establishing conclusive evidence of macrovascular disease risk reduction with colesevelam hydrochloride.
6 ADVERSE REACTIONS
The following important adverse reactions are described below and elsewhere in the labeling:
- Hypertriglyceridemia and Pancreatitis [see Warnings and Precautions (5.1)]
- Gastrointestinal Obstruction [see Warnings and Precautions (5.2)]
- Vitamin K or Fat-Soluble Vitamin Deficiencies [see Warnings and Precautions (5.3)]
6.1 Clinical Studies Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in clinical studies of another drug and may not reflect the rates observed in practice.
Primary Hyperlipidemia In 7 double-blind, placebo-controlled, clinical trials, 807 patients with primary hyperlipidemia (age range 18-86 years, 50% women, 90% Caucasians, 7% Blacks, 2% Hispanics, 1% Asians) and elevated LDL-C were treated with colesevelam hydrochloride 1.5 g/day to 4.5 g/day from 4 to 24 weeks (total exposure 199 patient-years).
Clinical Studies of Colesevelam Hydrochloride for Primary Hyperlipidemia: Adverse Reactions Reported in ≥ 2% of Patients and More Commonly than in Placebo
|Colesevelam hydrochloride N = 807||Placebo N = 258|
Pediatric Patients 10 to 17 Years of Age In an 8-week double-blind, placebo-controlled study boys and post-menarchal girls, 10 to 17 years of age, with HeFH (n=194), were treated with colesevelam hydrochloride tablets (1.9 to 3.8 g, daily) or placebo tablets
Clinical Study of Colesevelam Hydrochloride for Primary Hyperlipidemia in HeFH Pediatric Patients: Adverse Reactions Reported in ≥2% of Patients and More Commonly than in Placebo
|Colesevelam Hydrochloride N = 129||Placebo N = 65|
|Creatine Phosphokinase Increase||2.3%||0.0%|
The reported adverse reactions during the additional 18-week open-label treatment period with colesevelam hydrochloride 3.8 g per day were similar to those during the double-blind period and included headache (7.6%), nasopharyngitis (5.4%), upper respiratory tract infection (4.9%), influenza (3.8%), and nausea (3.8%).
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.